TemSujohn is a prescription medication specifically formulated for the management of moderate to severe chronic neuropathic pain. Developed through rigorous clinical research, it offers a targeted mechanism of action designed to modulate pain signaling pathways, providing sustained relief and improving functional outcomes. This treatment is indicated for patients who have not achieved adequate pain control with first-line therapies, offering a specialized option under professional supervision.

Features

• Active ingredient: TemSujohn hydrochloride 50 mg/100 mg
• Delayed-release tablet formulation
• Once-daily dosing regimen
• Bioavailability of approximately 92% with food
• Half-life of 16–22 hours
• Metabolized primarily via CYP3A4 pathway
• Available in 30-count and 90-count bottles

Benefits

• Provides significant reduction in neuropathic pain scores within 2–4 weeks of initiation
• Improves sleep quality and daily functioning by reducing nighttime pain interruptions
• Offers consistent 24-hour pain control with single daily dosing
• Demonstrates favorable tolerability profile compared to traditional neuropathic pain agents
• Reduces reliance on rescue medication for breakthrough pain
• Supports long-term pain management strategies with maintained efficacy

Common use

TemSujohn is primarily prescribed for diabetic peripheral neuropathy, postherpetic neuralgia, and chemotherapy-induced peripheral neuropathy. It may also be used off-label for other neuropathic pain conditions such as radiculopathy and complex regional pain syndrome when standard treatments prove insufficient. Clinical studies demonstrate particular effectiveness in patients with burning, shooting, or lancinating pain characteristics.

Dosage and direction

Initiate treatment at 50 mg once daily with the evening meal. After one week, based on tolerability and efficacy, the dose may be increased to 100 mg once daily—the maximum recommended dosage. Tablets must be swallowed whole and not crushed, chewed, or divided. Administration with food enhances absorption and reduces gastrointestinal side effects. Dose adjustments are necessary in patients with hepatic impairment (maximum 50 mg daily) and in those taking concomitant CYP3A4 inhibitors.

Precautions

Patients should be monitored for dizziness and somnolence, particularly during dose titration. Caution is advised when operating machinery until individual response is established. Regular assessment of renal function is recommended in patients with pre-existing renal impairment. Abrupt discontinuation may lead to withdrawal symptoms; taper gradually over at least one week. Pregnancy and breastfeeding considerations require careful risk-benefit assessment.

Contraindications

Hypersensitivity to TemSujohn or any component of the formulation. Severe hepatic impairment (Child-Pugh Class C). Concurrent use with strong CYP3A4 inducers. History of angioedema with previous TemSujohn use. Patients with uncontrolled narrow-angle glaucoma.

Possible side effects

Common (≥5%): dizziness (18%), somnolence (12%), dry mouth (9%), fatigue (7%), nausea (6%). Less common (1–5%): peripheral edema, blurred vision, weight gain, constipation. Rare (<1%): angioedema, hepatotoxicity, suicidal ideation. Most side effects are dose-dependent and often diminish with continued therapy.

Drug interaction

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) increase TemSujohn exposure—reduce dose by 50%. Strong CYP3A4 inducers (rifampin, carbamazepine) decrease efficacy—avoid concomitant use. Moderate interaction with alcohol, opioids, and other CNS depressants (additive sedation). Antacids may slightly decrease absorption—separate administration by 2 hours.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for the missed one. If multiple doses are missed, contact healthcare provider for guidance on re-titration to avoid adverse effects.

Overdose

Symptoms may include severe dizziness, sedation, confusion, and respiratory depression. Management is supportive with emphasis on maintaining airway and vital signs. Hemodialysis is not effective due to high protein binding. Contact poison control center immediately for guidance. Maximum tolerated single dose in clinical trials was 400 mg.

Storage

Store at 20–25°C (68–77°F) in original container with tight closure. Protect from moisture and light. Keep out of reach of children and pets. Discard any unused medication after expiration date. Do not transfer to other containers.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. TemSujohn is available by prescription only. Individual results may vary. Always follow your healthcare provider’s instructions regarding use, dosage, and monitoring. Report any adverse effects to your physician immediately.

Reviews

Clinical trial data (N=1,247) shows 68% of patients achieved ≥50% pain reduction at 12 weeks. Real-world evidence from post-marketing surveillance demonstrates sustained efficacy over 12 months with appropriate dose management. Patient-reported outcomes indicate significant improvements in quality of life measures and functional capacity. Healthcare providers note particular value in treatment-resistant cases where other modalities have failed.